The purpose of the present research work is to carryout pre-clinical and open clinical study on Benign Prostatic Hyperplasia. Clinically, BPH is distinguished by the progressive development of Lower Urinary Tract Syndrome (LUTS). According to NIH there are more than 7.8 million BPH diagnoses made per year. BPH is the 5th most prevalent non-cancer-related disorder among men aged 50 years and older. Economic burden of BPH accounts for seventh highest 1-year disease specific medical costs. The specific approach used to treat BPH depends upon number of factors like age, prostate size, weight, prostate-specific antigen level, and severity of the symptoms. The Herbo-mineral Siddha drug 'Velvanga Parpam' has unique effect on BPH, it decrease the solid tumour volume in drug treated animals and reduction of International Prostate Symptoms Score (IPSS) in BPH Patients. These data confirms that the Siddha drug 'Velvanga Parpam' can be used as a novel potential agent for BPH.